Latest International and Indian Pharma Company Announcements
Curated latest announcements on partnerships, product launches, regulatory approvals, M&A deals, and corporate developments from global and Indian pharmaceutical companies.
Corona Remedies Secures EU-GMP Certification for Hormone Facility
CORONA Remedies has received European Union Good Manufacturing Practice (EU-GMP) Compliance Certification for its hormone manufacturing facility and renewed EU-GMP approval for its Oral Solid Dosage (OSD) manufacturing facility at Bhayla, Ahmedabad. The Ahmedabad-based drug maker obtained EU GMP compliance certificate for its Bhayla facility following an EUDRA GMP inspection conducted in April 2026.
The certification covers primary packaging of Oral Solid Dosage products, including hormone-containing formulations. CORONA Remedies, backed by ChrysCapital, is a leading India-focused pharmaceutical company with strong presence in Women’s Healthcare, Cardio-Diabeto, Pain Management and Urology therapies. These accreditations strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets.
Date: May 28-31, 2026
Source: https://www.expresspharma.in/amp/corona-remedies-secures-eu-gmp-certification-for-hormone-facility-renews-approval-for-ahmedabad
Marksans Pharma to Acquire Netherlands-Based QliniQ B.V. for €7.5 Million
Marksans Pharma announced that it has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V., a profitable Netherlands-based pharmaceutical company with established front-end sales, marketing, and distribution capabilities across the Dutch healthcare market. The transaction, valued at €7,500,000, will be settled in cash, ensuring no equity dilution for Marksans shareholders.
The acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets. QliniQ reported revenue of €9.35M and net profit of €0.85M. The acquisition is expected to be completed by June 15, 2026, marking a strategic step in expanding Marksans’ presence across regulated European markets.
Date: May 31 – June 1, 2026
Source: https://www.business-standard.com/markets/capital-market-news/marksans-pharma-to-acquire-netherlands-based-qliniq-b-v-1260601005
Intracin Pharma Secures APVMA Nod to Supply Veterinary Medicines in Australia
Intracin Pharma secured regulatory clearance from APVMA (Australian Pesticides and Veterinary Medicines Authority) to supply veterinary medicines in Australia. This regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market.
The approval marks a significant milestone in Intracin Pharma’s international expansion strategy, enabling the company to serve the growing animal healthcare sector in one of the world’s most regulated markets.
Date: June 2, 2026
Source: https://www.indianpharmapost.com/news
Aragen Manufactures First GMP Batches of Daretabart
Aragen manufactures first GMP batches of Daretabart as part of its drug development program. Daretabart is a first-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept.
This milestone demonstrates Aragen’s capabilities in developing novel antibiotics for antimicrobial-resistant infections, an urgent global health priority.
Date: June 1, 2026
Source: https://www.expresspharma.in
CEPI Commits Up to $50 Million to Fund Moderna’s mRNA Vaccine Candidate
CEPI (Coalition for Epidemic Preparedness Innovations) will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate. The collaboration introduces a flexible, end-to-end CDx (companion diagnostic) framework designed to adapt to shifting regulatory environments.
This funding supports development of next-generation mRNA vaccines for infectious disease preparedness. CEPI’s investment demonstrates growing public-private partnerships in vaccine development and pandemic preparedness.
Date: June 2026
Source: https://www.indianpharmapost.com/news
Merz Bets on China Parkinson’s Treatment in $1.55 Billion Deal
Merz announced a strategic partnership for China Parkinson’s treatment with a transaction that includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments. This alliance highlights the growing trend of large-scale collaborations between biotech firms and global pharmaceutical giants.
The deal focuses on developing and commercializing novel Parkinson’s disease therapies in the Chinese market, addressing the growing unmet need for effective treatments.
Date: June 2, 2026
Source: https://www.thepharmaletter.com/pharma-news/india-s-pharmaceutical-future-from-generics-to-global-leadership
Company Receives 11 New Regulatory Approvals for Medicines and Indications
A leading pharmaceutical company announced receipt of 11 new regulatory approvals for medicines and indications, while oncology contributed Rs. 16,100.9 million to remain company’s largest therapy area. The company announced strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit.
These regulatory approvals expand the company’s portfolio across multiple therapeutic areas and strengthen its market position.
Date: June 2026
Source: https://www.indianpharmapost.com/news
Aflibercept Biosimilar Becomes Fifth Commercialized Biosimilar in Europe
A company announced that the aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments. This milestone demonstrates the company’s growing capabilities in biosimilar development and commercialization in regulated European markets.
The aflibercept biosimilar provides a more affordable treatment option for patients with wet age-related macular degeneration and other retinal diseases.
Date: June 2026
Source: https://www.indianpharmapost.com/news
SOS1 Inhibitor Shows Encouraging Safety Profile in First-in-Human Study
A first-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors. This development represents progress in targeted cancer therapy research for patients with advanced malignancies.
The SOS1 inhibitor is being evaluated for its potential to treat various KRAS-driven cancers, addressing a significant unmet medical need in oncology.
Date: June 2026
Source: https://www.indianpharmapost.com/news
FDA Approval Brings Mainstream Insurance Coverage for Obesity Treatment
The FDA move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach. This decision will significantly improve patient access to obesity treatments across the United States.
The expanded insurance coverage is expected to benefit millions of patients struggling with obesity and related metabolic conditions.
Date: June 2026
Source: https://www.indianpharmapost.com/news